December 31
by Jonathan Downham
Gavin and I try to peel apart the layers of the LeoPARDS Trial which assesses the benefits of levosimendan for the prevention of organ dysfunction in sepsis. It's another interesting study which actually asks more questions that it answers, but all questions we may try to answer one day with more research.
I am still hoping to get together with Danni Bear the dietician in the near future to talk about the latest findings from ASPEN. Watch this space.
Interview Questions for Advanced Critical Care Practitioners
The Content on the website is provided for FREE as is the podcast.
You could help support this work by going to Amazon via this link. This means that I will earn a small commission from any purchases you make with NO extra cost to yourself.
Thank you.
share this
Related Posts
Tom, one of my colleagues from the Critical Care Outreach Team and I discuss this paper and its findings reaching our own conclusions. Deferring Arterial Catheterisation in Patients with Septic Shock.
Read MoreWe return to our 48-year-old patient: jaundiced, hypotensive, drowsy, and bleeding. In decompensated cirrhosis, every treatment targets a disrupted system — splanchnic vasodilation, portal hypertension, toxin accumulation, and renal hypoperfusion.Although these patients look fluid overloaded, they are effectively hypovolaemic. Start with small aliquots of balanced crystalloid, avoiding 0.9% saline. In hepatorenal syndrome or tense ascites, 20% albumin is
Read MoreIn this episode, I walk through the real-world critical care management of acute decompensated alcohol-related liver disease, using a high-risk ICU case to anchor the discussion. The focus is on understanding the underlying physiology—portal hypertension, rebalanced haemostasis, hepatic encephalopathy, infection, and hepatorenal syndrome—and translating that physiology into clear first-hour priorities at the bedside. Listeners are
Read More